Techne, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $297.03 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 4.11%.

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific ...

Keybank National Association OH boosted its position in shares of Bio-Techne Co. (NASDAQ:TECH – Free Report) by 66.4% in the ...

Deutsche Bank placed at “Catalyst Call: Buy” on shares of Bio-Techne (TECH) as a short-term investment idea. The firm expects Bio-Techne to report fiscal Q3 results in line or above consensus ...

TECHNE is a practice-based digital arts research initiative founded by Professor Mark Amerika, at the University of Colorado at Boulder. The TECHNE initiative develops innovative approaches to the ...

Zurcher Kantonalbank Zurich Cantonalbank decreased its holdings in shares of Bio-Techne Co. (NASDAQ:TECH – Free Report) by 2.8% in the 4th quarter, according to the company in its most recent Form 13F ...

Bio-Techne Corp. TECH recently launched an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology research and the development of next-generation ...

The $40m tower proposal was granted a planning permit by the Hobart City Council last year and the proponent, Techne Invest, which counts former AFL star Nick Riewoldt as one of its directors ...

Headquartered in Minneapolis, Minnesota, Bio-Techne Corporation (TECH) is a leading provider of life sciences solutions dedicated to advancing biomedical research and diagnostics. With a market ...

(RTTNews) - Bio-Techne Corp. (TECH) announced earnings for its second quarter that increased from last year and beat the Street estimates. The company's bottom line totaled $34.89 million ...